MedDataX Logo

Comparison of Bupivacaine and Exparel for Carpal Tunnel Release

NCT ID: NCT02141178

Last Updated: 2016-01-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2015-05-31

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Carpal tunnel syndrome is one of the most common surgeries performed per year in the United States, accounting for over 600,000 surgeries. The procedure is commonly performed under light sedation and local anesthesia. Bupivicaine, a long acting local anesthetic, has been used to allow extended pain relief for 8-10 hours after carpal tunnel release. Exparel, a liposomal bupivicaine formulation, has been documented to provide pain relief for up to 72 hours post-operatively. By decreasing post-operative pain through the use of a long-acting local anesthetic, the use of narcotic pain medications may be decreased and patient satisfaction scores may increase.

The purpose of this study is to prospectively compare bupivicaine and liposomal bupivicaine with respect to post-operative pain control, narcotic usage, and patient satisfaction after carpal tunnel release.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Supraclavicular Bupivacaine Vs. Supraclavicular Liposomal Bupivacaine for Orthopedic Wrist Surgery

NCT06179004

Distal Radius Fractures Wrist Fractures
RECRUITING PHASE3

Early Post-Operative Pain Control Following Wrist Operations

NCT02052180

Pain
UNKNOWN NA

Study of A Long Lasting Local Anesthestic for Hand, Wrist or Finger Surgery

NCT02058303

Hand Injuries Wrist Injuries Finger Injuries
TERMINATED PHASE4

Exparel for Postoperative Pain Management in Shoulder Surgery

NCT02472314

Fracture of Shoulder and Upper Arm
COMPLETED PHASE4

Phase 4, Controlled Study in Adult Subjects Undergoing Primary, 1-2 Level, Open Lumbar Spinal Fusion Surgery

NCT03015961

Postoperative Pain Management
TERMINATED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain After Carpal Tunnel Release

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bupivacaine

Patients will received 0.5% Bupivacaine subcutaneously for local anesthesia during surgery

Group Type ACTIVE_COMPARATOR

Bupivacaine

Intervention Type DRUG

Exparel

Patients will received Exparel subcutaneously for local anesthesia during surgery

Group Type EXPERIMENTAL

Exparel

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bupivacaine

Intervention Type DRUG

Exparel

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with carpal tunnel syndrome undergoing surgery

Exclusion Criteria

* Non english speaking
* Allergy to bupivacaine or exparel
Minimum Eligible Age

18 Years

Maximum Eligible Age

89 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Pittsburgh

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PRO14040418

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pharmacokinetics and Safety of Bupivacaine HCl Spinal Block and EXPAREL Local Infiltration in Total Knee Arthroplasty
NCT02284386 COMPLETED PHASE4
Exparel Use in Bilateral TAP Blocks for Postoperative Pain Control
NCT03878888 COMPLETED PHASE4
A Prospective Study to Compare Bupivacaine and Exparel Versus Bupivacaine or Exparel Alone for Postoperative Pain Relief
NCT03514277 TERMINATED PHASE4
Exparel Use in Adductor Canal Block After Total Knee Arthroplasty
NCT04910165 COMPLETED PHASE3
Efficacy of Liposomal Bupivacaine for Prolonged Postoperative Analgesia in Patient Undergoing Breast Reconstruction With Tissue Expander
NCT04278846 COMPLETED PHASE4
Liposomal Bupivacaine (Exparel) for Postoperative Pain Control for Open and Laparoscopic Abdominal Hernia Repair
NCT02128646 COMPLETED PHASE4
Post Operative Pain Control for Distal Radius Surgery: Does Exparel Injected at the Surgery Site Improve Postoperative Pain Scores at 24 and 48 Hours ?
NCT04540848 WITHDRAWN PHASE4
Liposomal Bupivacaine Versus Interscalene Nerve Block
NCT03929146 COMPLETED PHASE4
PAIN - Postoperative Analgesia INvestigation
NCT02111746 COMPLETED PHASE4
Liposomal Bupivacaine in Total Knee Arthroplasty
NCT03541265 COMPLETED NA
Femoral Nerve Block With Liposome Bupivacaine for Postsurgical Analgesia Following Total Knee Arthroplasty
NCT01683071 COMPLETED PHASE2/PHASE3
Bupivacaine Versus Lidocaine Local Anesthesia
NCT01751347 COMPLETED PHASE4
0.25% Bupivacaine Versus a Mixture of 0.25% Bupivacaine and 1.3 % Liposomal Bupivacaine in Patients Undergoing Tka
NCT03303794 TERMINATED PHASE3
Multimodal Pain Management Following Primary TKA
NCT02369523 TERMINATED EARLY_PHASE1
Liposomal Bupivacaine in One-level Instrumented Posterior Spinal Fusion
NCT03745040 SUSPENDED PHASE4
Exparel vs. Standard Bupivicaine for Abdominoplasty
NCT01853176 TERMINATED PHASE4
Exparel Use in Peripheral Nerve Blocks and Local Infiltration for Foot and Ankle Surgery: A Randomized Controlled Trial
NCT05494645 UNKNOWN PHASE4
Liposomal Bupivacaine Infiltration vs Continuous Perineural Ropivacaine Infusion for Post-operative Pain After Total Shoulder Arthroplasty
NCT02787226 TERMINATED PHASE4
Intraoperative Liposomal Bupivacaine Injection in Primary Total Knee Arthroplasty
NCT02341079 WITHDRAWN PHASE2/PHASE3
Comparison of Exparel to Marcaine in Post-Surgical Analgesia in Bariatrics
NCT02752230 WITHDRAWN PHASE4
Liposomal Bupivacaine in Rotator Cuff Repair
NCT03738696 COMPLETED PHASE4
Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of EXPAREL, EXPAREL Admixed With Bupivacaine HCl vs. Bupivacaine HCl Administered as Combined Sciatic and Saphenous Nerve Blocks for Postsurgical Analgesia in Subjects Undergoing Lower Extremity Surgeries
NCT04518462 COMPLETED PHASE3
Exparel Injection for Postoperative Orbital Pain
NCT02381353 ACTIVE_NOT_RECRUITING PHASE4
EXPAREL Infiltration in Subjects Undergoing Femoral Nerve Block With Bupivacaine HCl for Total Knee Arthroplasty
NCT02255500 COMPLETED PHASE4
Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of EXPAREL® Administered Via a Single Intrathecal Injection to Healthy Volunteers
NCT04173611 TERMINATED PHASE1